AI Article Synopsis

  • The study aims to compare the effectiveness of transarterial chemoembolization (TACE) combined with lenvatinib and tislelizumab (TLT) versus TACE combined with lenvatinib (TL) for treating unresectable hepatocellular carcinoma.
  • A total of 169 patients participated, with those receiving TLT showing superior overall survival (26 months) and progression-free survival (14 months) compared to the TL group (20 months and 9 months, respectively).
  • Results indicated that specific patient groups, particularly those with larger tumors and certain health markers, benefited significantly from the TLT treatment over TL.

Article Abstract

Objective: Comparing the efficacy of transarterial chemoembolization (TACE) combined with lenvatinib plus tislelizumab (TLT) with TACE combined with lenvatinib (TL) for unresectable hepatocellular carcinoma, particularly in determining which patients can benefit more from the TLT treatment.

Methods: From March 2021 to September 2023, a total of 169 patients from three centers were included in this study, with 103 patients receiving TLT and 66 patients receiving TL. The Kaplan-Meier method was utilized to evaluate the cumulative overall survival (OS) and progression-free survival (PFS) between the two groups and were assessed using the log-rank test. Subgroup analysis on tumor number, maximum tumor diameter, presence of portal vein thrombosis, AFP level, and Child-Pugh class were conducted.

Results: The median OS was 26 months in the TLT group, and 20 months in the TL group. The median PFS was 14 months in the TLT group and 9 months in the TL group. The Kaplan-Meier curve demonstrated a significantly superior OS and PFS in the TLT group compared to the TL group. Subgroup analysis showed that for patients with a maximum tumor diameter greater than 7 cm, AFP > 400 ng/ml and accompanied by portal vein tumor thrombus, and Child-Pugh class A, there was a statistically significant difference in OS between TLT and TL groups.

Conclusions: OS and PFS were significantly improved in patients who received TLT compared to those who received TL, patients with a largest tumor diameter greater than 7 cm, AFP > 400 ng/ml, Child-Pugh class A and PVTT appeared to derive more benefit.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473327PMC
http://dx.doi.org/10.3389/fimmu.2024.1449663DOI Listing

Publication Analysis

Top Keywords

combined lenvatinib
12
tumor diameter
12
child-pugh class
12
tlt group
12
transarterial chemoembolization
8
lenvatinib tislelizumab
8
unresectable hepatocellular
8
hepatocellular carcinoma
8
tace combined
8
tlt
8

Similar Publications

Article Synopsis
  • Primary liver cancer, mainly hepatocellular carcinoma (HCC), is a major cause of cancer deaths, and tumor thrombus (TT) in major vessels worsens patient outcomes.
  • Four male HCC patients (average age 57) with TT in the inferior vena cava or right atrium underwent surgery to remove the tumors, followed by targeted and immunotherapy.
  • All cases show positive outcomes post-treatment, with some patients remaining disease-free for up to 74 months, suggesting that combining surgery with therapy could improve survival rates in advanced HCC patients.
View Article and Find Full Text PDF

The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively.

View Article and Find Full Text PDF

Anaplastic thyroid cancer (ATC) is the most lethal tumor arising from thyroid follicular epithelium. Lenvatinib is an off-label use option for ATC patients in many countries but an approved prescription in Japan. However, lenvatinib resistance is a substantial clinical challenge.

View Article and Find Full Text PDF

Introduction: To identify prognostic biomarkers that could predict how well patients will respond to lenvatinib/pembrolizumab (LEN/PEM). The utility of certain inflammatory biomarkers in endometrial liquid-based cytology (LBC) or peripheral blood samples, such as neutrophil counts, lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR) were explored.

Methods: The study included 25 patients with advanced or recurrent endometrial cancer who had received LEN/PEM between August 2018 and March 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!